The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

Görgel, Sacit Nuri; Şefik, Ertuğrul; Köse, Osman; Olğunelma, Vural; Şahin, Evren

doi:10.1590/s1677-5538.ibju.2013.05.07

Cited by 20 publications

(20 citation statements)

References 27 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rofecoxib monotherapy and combination of rofecoxib and 5α−reductase inhibitor finasterid were evaluated in patients with LUTS/BPO [19]. Tenoxicam plus α−adrenergic antagonist doxazosin, celecoxib plus doxazosin and meloxicam plus another α−adrenergic antagonist tamsulosin were the other combinations investigated [20,21,22]. Tenoxicam, refecoxib and meloxicam are known as COX−2 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms

Gökkaya¹,

Aktaş²,

Özden³

et al. 2015

CEJU

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms

Gökkaya¹,

Aktaş²,

Özden³

et al. 2015

CEJU

View full text Add to dashboard Cite

“…30 The daily use of non-steroidal anti-inflammatory drugs prevents an increase of prostate volume 31 and the treatment with a COX-2 inhibitor combined with an α 1 -adrenoceptor blocker or a 5α-reductase inhibitor improves urinary flow rate. 32–34 In addition, COX-2 inhibitors decrease androgen receptor activity in prostate cancer cells. 35 These observations suggest that COX-2 may represent a convergent mediator of prostate growth in the inflammatory pathway.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies have reported high BCL-2 expression in BPH tissue specimens accompanied with chronic inflammation [30]. The daily use of nonsteroidal anti-inflammatory drugs prevents an increase of prostate volume [31] and the treatment with a COX-2 inhibitor combined with an a 1 -adrenoceptor blocker or a 5a-reductase inhibitor improves urinary flow rate [32][33][34]. In addition, COX-2 inhibitors decrease androgen receptor activity in prostate cancer cells [35].…”

Section: Discussionmentioning

confidence: 99%

Influence ofE. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats

et al. 2014

View full text Add to dashboard Cite

Background Prostatic inflammation is reportedly associated with the development of prostatic hyperplasia. We investigated the effects of prostatic inflammation on expression levels of androgen-responsive genes and growth factors in the rat prostate. Methods Prostatic inflammation was induced by Escherichia coli (strain 1677) injection (0.2 mL of 1 × 108 CFU/mL) into the prostatic urethra of male Sprague-Dawley rats, and ventral lobes of the prostate were harvested on day 84. Rats were given 10 mg/kg celecoxib during the last month in the COX-2 inhibitor treated group. Histopathology and multiplex ELISA for inflammation-related proteins were performed. Glandular epithelial cells and stromal regions were separately isolated using laser-capture microdissection (LCM). Real-time RT-PCR was performed to examine mRNA levels of androgen-responsive genes in the epithelium and TGF-β1 cascade genes in the stroma. Results Hematoxylin and eosin staining showed that mild inflammation was distributed diffusely throughout the prostate. Polymorphonuclear cells infiltrated the slightly edematous stroma, but no morphological changes were observed in the epithelium. Immunohistochemically, expression of androgen receptor and TGF-β1 in addition to IL-6 and COX-2 were enhanced in the E. coli inoculated rats. All of these factors were suppressed in the celecoxib-treated rats. Upregulation of IL-1α, IL-1β, IL-6, and RANTES in the E. coli-inoculated rats was normalized by celecoxib treatment. Significant upregulation of androgen receptor and androgen-responsive genes such as Eaf2, ELL2, FKBP5, calreticulin and ornithine decarboxylase was observed in the LCM-dissected epithelium. Also TGF-β1 and its downstream cascade genes such as Hic-5, collagen 1, and fibronectin were upregulated significantly in the LCM-dissected stroma. The COX-2 inhibitor treatment suppressed upregulation of these genes. Conclusions Prostatic inflammation changed the expression of androgen-responsive genes in the epithelium and TGF-β1 cascade genes in the stroma. Activation of TGF-β1 cascade genes in the inflamed stroma, as well as altered androgen-responsive gene expression in the epithelium, might be involved in the development of BPH.

show abstract

“…PG synthesis inhibitors reduce void frequency and volume in enuresis, indomethacin relieves symptoms of BPH, aspirin and diclofenac relieve nocturnal polyuria symptoms, diclofenac improves nocturnal polyuria symptoms, and celecoxib reduces NV and International Prostate Symptom Scores . Tamsulosin and meloxicam combination has been shown to improve symptoms and NQOL scores greater than tamsulosin alone …”

Section: Introductionmentioning

confidence: 99%

“…16 Tamsulosin and meloxicam combination has been shown to improve symptoms and NQOL scores greater than tamsulosin alone. 17 The current study used ibuprofen and acetaminophen because they have synergy in analgesic effect, [18][19] which may also alleviate nocturia. Concurrent administrations of ibuprofen and acetaminophen are free of drug-to-drug interactions, and show no changes in pharmacokinetics or bioavailability compared to either drug alone.…”

Section: Introductionmentioning

confidence: 99%

Novel immediate/sustained‐release formulation of acetaminophen‐ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi‐center, randomized, double blinded, placebo‐controlled, 4‐arm trial

Lee

Rauscher

Kaminesky

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aim To determine short‐term efficacy and safety of Paxerol®, novel immediate:sustained (50%:50%) release tablets containing 325 mg acetaminophen and 150 mg ibuprofen per tablet. Methods One of three dose levels, corresponding to the amounts in 1, 2, and 3 tablets, of Paxerol and placebo were administered for 14 consecutive days to patients with severe nocturia (defined in this study as an average nocturnal voids [NV] ≥2.5) associated with overactive bladder (OAB). Changes in NV, as well as Nocturia Quality of Life (NQOL), duration of first uninterrupted sleep (DFUS), and total hours of nightly sleep (THNS) associated with treatment were assessed. Short‐term safety/tolerability was assessed throughout the study and for at least 30 days post‐treatment. Results Paxerol at all three doses reduced NV to a greater degree than placebo (average NV −1.1, −1.4, −1.3 voids for low, mid, and high doses, respectively, vs −0.3 void for placebo). NQOL and THNS were similar between baseline and treatment values in all four groups. There were also no between‐group differences. Paxerol at high dose tended to (although not statistical significantly) increase DFUS to a greater degree than placebo (1.2 vs 0.4 h, P = 0.057). There were no treatment related adverse events in any of the four groups. Conclusions This study demonstrates short‐term efficacy and short‐term safety of Paxerol in patients with severe nocturia associated with OAB. The results warrant further investigation of the long‐term efficacy and safety of Paxerol in larger patient populations.

show abstract

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

Cited by 20 publications

References 27 publications

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms

Influence ofE. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats

Novel immediate/sustained‐release formulation of acetaminophen‐ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi‐center, randomized, double blinded, placebo‐controlled, 4‐arm trial

Contact Info

Product

Resources

About